Literature DB >> 22009249

Dialysis: ESA responsiveness and outcomes in patients on hemodialysis.

Steven Fishbane, Azzour Hazzan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22009249     DOI： 10.1038/nrneph.2011.169

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  8 in total

Review 1.  Recent advances in erythropoietic agents in renal anemia.

Authors:  Iain C Macdougall
Journal:  Semin Nephrol       Date:  2006-07       Impact factor: 5.299

2.  Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis.

Authors:  Arintaya Phrommintikul; Steven Joseph Haas; Maros Elsik; Henry Krum
Journal:  Lancet       Date:  2007-02-03       Impact factor: 79.321

Review 3.  Recombinant human erythropoietin: has treatment reached its full potential?

Authors:  Steven Fishbane
Journal:  Semin Dial       Date:  2006 Jan-Feb       Impact factor: 3.455

4.  Hematocrit level and associated mortality in hemodialysis patients.

Authors:  J Z Ma; J Ebben; H Xia; A J Collins
Journal:  J Am Soc Nephrol       Date:  1999-03       Impact factor: 10.121

5.  Epoetin requirements predict mortality in hemodialysis patients.

Authors:  Yi Zhang; Mae Thamer; Kevin Stefanik; James Kaufman; Dennis J Cotter
Journal:  Am J Kidney Dis       Date:  2004-11       Impact factor: 8.860

6.  Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan.

Authors:  Shingo Fukuma; Takuhiro Yamaguchi; Seiji Hashimoto; Shigeru Nakai; Kunitoshi Iseki; Yoshiharu Tsubakihara; Shunichi Fukuhara
Journal:  Am J Kidney Dis       Date:  2011-09-03       Impact factor: 8.860

7.  Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol.

Authors:  Giovanni F M Strippoli
Journal:  Trials       Date:  2010-06-09       Impact factor: 2.279

8.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Authors:  Marc A Pfeffer; Emmanuel A Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto
Journal:  N Engl J Med       Date:  2009-10-30       Impact factor: 91.245
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.